The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 401–500 of 1,001
The roles of small‐molecule inflammatory mediators in rheumatoid arthritis
Cheng, Q., Wu, H., & Du, Y. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12982 · Cited by 41
Arnold, W. R., Carnevale, L. N., Xie, Z., Baylon, J. L., Tajkhorshid, E., Hu, H., & Das, A. (2021) · Nature Communications · doi:10.1038/s41467-021-20946-6 · Cited by 40
Lingegowda, H., Williams, B. J., Spiess, K. G., Sisnett, D. J., Lomax, A. E., Koti, M., & Tayade, C. (2022) · Journal of Cannabis Research · doi:10.1186/s42238-022-00163-8 · Cited by 40
The Basic Science of Cannabinoids
Sideris, A., Lauzadis, J., & Kaczocha, M. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006472 · Cited by 40
Laere, K. V., Koole, M. J. B., Bohorquez, S. M. S., Goffin, K. E., Guenther, I., Belanger, M.-J., Côté, J., Rothenberg, P., Lepeleire, I. D., Grachev, I. D., et al. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047290 · Cited by 40
“Nevertheless, the suspected role of CB1Rs in bowel inflammatory disorders and motility disturbances as well as obesity (1) might still be studied dynamically by early PET in patients to further elucidate possible diagnostic applications of 18F-MK-9470.”
BackgroundMapping eQTLs in the Norfolk Island Genetic Isolate Identifies Candidate Genes for CVD Risk Traits
Benton, M. C., Lea, R. A., Macartney-Coxson, D. P., Carless, M. A., Göring, H. H. H., Bellis, C., Hanna, M., Eccles, D., Chambers, G. K., Curran, J. E., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.11.004 · Cited by 40
“NAAA is involved in the endocannabinoid system, which has been implicated in obesity through its ability to attenuate or lower the desire of finding and consuming food.(49,50) Because FN3KRP has been tentatively suggested to associate with diabetes, measurement of FN3K and FN3KRP activity might be of diagnostic value…”
BackgroundKruk-Słomka, M., Boguszewska‐Czubara, A., Słomka, T., Budzyńska, B., & Biała, G. (2015) · Neural Plasticity · doi:10.1155/2016/9815092 · Cited by 40
Central functional response to the novel peptide cannabinoid, hemopressin
Dodd, G. T., Worth, A. A., Hodkinson, D. J., Srivastava, R. K., Lutz, B., Williams, S. R., & Luckman, S. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.007 · Cited by 40
“When released into the synaptic cleft, endocannabinoids activate presynaptic cannabinoid 1 (CB1) receptors, and impart an inhibitory action on further presynaptic transmission (Di Marzo et al., 2004; Wilson and Nicoll, 2002).”
BackgroundPastuhov, S. I., Matsumoto, K., & Hisamoto, N. (2016) · Genes to Cells · doi:10.1111/gtc.12377 · Cited by 40
Contribution of CB1 blockade to the management of high-risk abdominal obesity
Després, J., Lemieux, I., & Alméras, N. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803278 · Cited by 40
Anandamide Protects from Low Serum-induced Apoptosis via Its Degradation to Ethanolamine
Matas, D., Juknat, A., Pietr, M., Klin, Y., & Vogel, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608646200 · Cited by 40
Garai, S., Leo, L. M., Szczesniak, A.-M., Hurst, D. P., Schaffer, P. C., Zagzoog, A., Black, T., Deschamps, J. R., Miess, E., Schulz, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00040 · Cited by 39
Naderi, N., Ahmad-Molaei, L., Ahari, F. A., & Motamedi, F. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0479-1 · Cited by 39
“It has been shown that MAGL for 2-AG inactivation is localized in presynaptic terminals [29] which supports a possible role as retrograde messenger at presynaptic CB1 receptors for this compound [30] whereas FAAH seems to be most abundant on neurons postsynaptic to CB1 receptors [31] indicating that anandamide acts pr…”
BackgroundThe molecular connections between the cannabinoid system and endometriosis
Sanchez, A. M., Vigano, P., Mugione, A., Panina-Bordignon, P., & Candiani, M. (2012) · Molecular Human Reproduction · doi:10.1093/molehr/gas037 · Cited by 35
“Anandamide is synthesized from its precursor N-acylphosphatidylethanolamine (NAPE) by the NAPEphospholipase D (NAPE-PLD) (Di Marzo et al., 2004).”
BackgroundWojtalla, A., Herweck, F., Granzow, M., Klein, S., Trebicka, J., Huss, S., Lerner, R., Lutz, B., Schildberg, F. A., Knolle, P. A., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00241.2011 · Cited by 39
“Since endocannabinoids exhibit a volatile nature with short half-life due to their production on demand without storage capability and fast degradation (16), the rapid induction of cell death in primary HSCs by NADA shown in vitro implies a putative effective induction of death in vivo.”
InfluentialCurrent Concepts and Controversies in Innate Immunity of Cystic Fibrosis Lung Disease
Ralhan, A., Laval, J., Lelis, F., Ballbach, M., Grund, C., Hector, A., & Hartl, D. (2016) · Journal of Innate Immunity · doi:10.1159/000446840 · Cited by 39
Ngo, S. T., Mi, J. D., Henderson, R. D., McCombe, P., & Steyn, F. J. (2017) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s120607 · Cited by 39
“Cannabinoids (CBs) such as THC modulate their effects via CB receptors expressed throughout the brain (predominantly CB1 receptors) and immune system (predominantly CB2 receptors).(48) The reader is encouraged to consult recent reviews on the use”
BackgroundTonstad, S. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.011 · Cited by 39
“A comprehensive review of the system has recently been published [5].”
BackgroundSathyapalan, T., Cho, L. W., Kilpatrick, E. S., Coady, A., & Atkin, S. L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03260.x · Cited by 32
Hemp Biomass as a Raw Material for Sustainable Development
Sieracka, D., Frankowski, J., Wacławek, S., & Czekała, W. (2023) · Applied Sciences · doi:10.3390/app13179733 · Cited by 38
Lowe, D. J. E., Sorkhou, M., & George, T. P. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2023.2299922 · Cited by 40
Ellsworth, B. A., Wang, Y., Zhu, Y., Pendri, A., Gerritz, S. W., Sun, C., Carlson, K. E., Kang, L., Baska, R. A. F., Yang, Y., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.087 · Cited by 38
Olmo, I. G., Ferreira-Vieira, T. H., & Ribeiro, F. M. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104372 · Cited by 38
“…biochemical machinery for endocannabinoid synthesis and degradation, and the cannabinoid receptors, which include the cannabinoid type 1 (CB1) receptor, the cannabinoid type 2 receptor, and possibly others (Mechoulam et al., 1995; Piomelli, 2003; Di Marzo et al., 2004; DiMarzo, 2008).”
Endocannabinoids, stress signaling, and the locus coeruleus-norepinephrine system
Wyrofsky, R. R., Reyes, B. A. S., Zhang, X.-Y., Bhatnagar, S., Kirby, L. G., & Bockstaele, E. J. V. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100176 · Cited by 38
Cannabinoids: a class of unique natural products with unique pharmacology
Piscitelli, F., & Marzo, V. D. (2021) · RENDICONTI LINCEI · doi:10.1007/s12210-020-00966-y · Cited by 38
Self-citationRice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 38
Polypharmacology Shakes Hands with Complex Aetiopathology
Brodie, J., Marzo, V. D., & Guy, G. W. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.010 · Cited by 38
Self-citationPratt–Hyatt, M., Zhang, H., Snider, N. T., & Hollenberg, P. F. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033712 · Cited by 38
“Numerous results have illuminated how this complex system assists in controlling a wide variety of psychological and physiological processes including mood, appetite, inflammation, and pain sensation (Richardson et al., 1998; Di Marzo et al., 2004).”
BackgroundBlood–Brain Barrier Pathophysiology following Traumatic Brain Injury
Laskowitz, D., & Grant, G. A. (2015) · CRC Press eBooks · doi:10.1201/b18959-9 · Cited by 38
Pharmacologic Treatment of Obesity
Sidhaye, A. R., & Cheskin, L. J. (2006) · KARGER eBooks · doi:10.1159/000090962 · Cited by 38
The burden of type 2 diabetes: strategies to prevent or delay onset.
Iqbal, N. (2007) · PubMed Central · Cited by 38
Emerging Therapeutic Role of PPAR–α in Cognition and Emotions
Nisbett, K. E., & Pinna, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00998 · Cited by 37
Yousefi, B., Farjad, M., Nasehi, M., & Zarrindast, M. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.12.001 · Cited by 37
Shah, S., Gupta, A. S., & Kumar, P. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_488_18 · Cited by 37
Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors
Aghaei, I., Rostampour, M., Shabani, M., Naderi, N., Motamedi, F., Babaei, P., & Khakpour-Taleghani, B. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.08.010 · Cited by 37
Gupta, S., Bharatha, A., Cohall, D., Rahman, S., Haque, M., & Majumder, M. A. A. (2024) · Cureus · doi:10.7759/cureus.55468 · Cited by 36
“CB 1 R and CB 2 R have been cloned [31,32], cementing their roles as primary targets for eCBs [29,30].”
BackgroundNew tetrazole-based selective anandamide uptake inhibitors
Ortar, G., Moriello, A. S., Cascio, M. G., PETROCELLIS, L. D., Ligresti, A., Morera, E., Nalli, M., & Marzo, V. D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.003 · Cited by 36
Self-citationSmall animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa
Casteels, C., Gérard, N., van Kuyck, K., Pottel, L., Nuttin, B., Bormans, G. M., & Laere, K. V. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2522-8 · Cited by 36
“CB1 receptors are abundantly expressed presynaptically to directly or indirectly modulate major neurotransmitters such as glutamate, gammaaminobutyric acid (GABA) and dopamine [6, 7].”
BackgroundNavarrete, C. M., Fiebich, B. L., de Vinuesa, A. G., Hess, S., de Oliveira, A. C. P., Candelario‐Jalil, E., Caballero, F. J., Calzado, M. A., & Muñóz, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05966.x · Cited by 36
Bergholm, R., Sevastianova, K., Santos, A., Kotronen, A., Urjansson, M., Hakkarainen, A., Lundbom, J., Tiikkainen, M., Rissanen, A., Lundbom, N. M. I., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.116 · Cited by 36
Cannabinoid receptor CB2 protects against balloon-induced neointima formation
Molica, F., Matter, C. M., Burger, F., Pelli, G., Lenglet, S., Zimmer, A., Pacher, P., & Steffens, S. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00444.2011 · Cited by 36
“The development of selective CB2 receptor agonists for therapeutic applications, devoid of psychoactive properties attributable to CB1 activation, has attracted considerable interest over the past years (9, 17).”
BackgroundScott, K. A., Shah, S., Dalgleish, A. G., & Liu, W. M. (2013) · PubMed · Cited by 36
Marino, S., & Idris, A. I. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.023 · Cited by 36
“The endocannabinoid system onsists of a family of receptors, endogenous ligands and the olecular machinery for their synthesis, transport and metabolism reviewed in [3]).”
BackgroundSenn, R., Keren, O., Hefetz, A., & Sarne, Y. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.08.005 · Cited by 36
Smoking Cessation Pharmacotherapy—Nicotine and Non‐Nicotine Preparations
Frishman, W. H. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.05963.x · Cited by 36
Differential Modulation of Nociceptive versus Non-Nociceptive Synapses by Endocannabinoids
Higgins, A. S., Yuan, S., Wang, Y., & Burrell, B. D. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-26 · Cited by 35
“Background Endogenous cannabinoids (endocannabinoids or eCBs), such as anandamide and 2-arachidonoyl glycerol (2AG), are lipid neurotransmitters found throughout the central nervous system of both vertebrates and invertebrates that modulate a number of behavioral processes including appetite, cognition, emotion, senso…”
BackgroundNiloy, N., Hediyal, T. A., Vichitra, C., Sharma, S., Chidambaram, S. B., Gorantla, V. R., & Mahalakshmi, A. M. (2023) · Biomolecules · doi:10.3390/biom13010162 · Cited by 35
Dodd, G. T., Stark, J. A., McKie, S., Williams, S. R., & Luckman, S. M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.022 · Cited by 35
Yasuo, S., Koch, M., SCHMIDT, H. J., Ziebell, S., Bojunga, J., Geißlinger, G., & Korf, H. (2010) · Cell and Tissue Research · doi:10.1007/s00441-010-0930-7 · Cited by 35
“... provide the first experimental evidence for the presence of an intrinsic endocannabinoid system in the PT. As shown by in situ hybridization and immunohistochemistry, the PT expresses enzymes involved in the synthesis and degradation of two major endocannabinoids, viz., AEA and 2-AG, which are involved in the cont…”
BackgroundInfluentialBeneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC
Sarne, Y. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1578366 · Cited by 35
Calcium and endocannabinoids in the modulation of inhibitory synaptic transmission
Diana, M. A., & Bregestovski, P. D. (2005) · Cell Calcium · doi:10.1016/j.ceca.2005.01.020 · Cited by 35
Rahman, S., Ayyagari, A., Dutta, D., Kumar, V., Kim, J., Jan, A. T., & Minakshi, R. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.01.005 · Cited by 34
“…phospholipase D (NAPE-PLD) to give anandamide; on the other hand glycerophospholipid is acted upon by phospholipase C (PLC) to give sn -1-Acyl-2-arachidonyl glycerol that gives 2-AG under the enzymatic activity of sn -1-selective diacylglycerol lipases (DAGLs) (Di Marzo et al., 2004).”
Laaboudi, F.-Z., Rejdali, M., Amhamdi, H., Salhi, A., Elyoussfi, A., & Ahari, M. (2024) · Toxicology Reports · doi:10.1016/j.toxrep.2024.101685 · Cited by 34
“Nevertheless, research progress regarding its medicinal beneficial effects was hindered due to prejudice and misinformation, [111,66,73] and the financial significance of its seeds became negligible by the mid-20th century, as they were mainly utilized as animal feed and, sometimes, consumed by…”
BackgroundCannabinoids and cancer pain: A new hope or a false dawn?
Brown, M. R. D., & Farquhar-Smith, W. P. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.020 · Cited by 34
Rafiei, D., & Kolla, N. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031047 · Cited by 34
“NAPE-PLD and DAGL are stimulated by high calcium concentrations; therefore, calcium influx into the postsynaptic neuron is thought to trigger biosynthesis of AEA and 2-AG [10].”
BackgroundInfluentialFloreani, A., Lazzari, R., Macchi, V., Porzionato, A., Variola, A., Colavito, D., Leon, A., Guido, M., Baldo, V., De, R., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0122-y · Cited by 34
“cardiovascular function and the immune and inflammatory responses [1, 2].”
BackgroundDiarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
Kim, J. Y., Seo, H. J., Lee, S.-H., Jung, M. E., Ahn, K., Kim, J., & Lee, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.130 · Cited by 34
PUFA-derived endocannabinoids: an overview
Cascio, M. G. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003418 · Cited by 34
Zádor, F., Nagy-Grócz, G., Kékesi, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Horváth, G., Benyhe, S., & Vécsei, L. (2019) · Molecules · doi:10.3390/molecules24203709 · Cited by 34
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 34
Myllymäki, M. J., Käsnänen, H., Kataja, A. O., Lahtela-Kakkonen, M. K., Saario, S. M., Poso, A., & Koskinen, A. M. P. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.05.012 · Cited by 34
The Endocannabinoid System: Mechanisms Behind Metabolic Homeostasis and Imbalance
Woods, S. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.11.013 · Cited by 34
Espinosa‐Riquer, Z. P., Ibarra-Sánchez, A., Vibhushan, S., Bratti, M., Charles, N., Blank, U., Rodríguez–Manzo, G., & González‐Espinosa, C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800997 · Cited by 33
“enzymatic systems involved in their biosynthesis and degradation (6).”
BackgroundDasram, M. H., Walker, R. B., & Khamanga, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113223 · Cited by 33
“Experimental models of different disorders involving the endocannabinoid system revealed the ECS to exhibit a protective function or a contribution to the symptoms and progression of disease [179].”
BackgroundCannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Idris, A. I. (2010) · Current Neuropharmacology · doi:10.2174/157015910792246173 · Cited by 33
“CB1 and CB2 receptors are coupled to adenylyl cyclase and cyclic adenosine monophosphate (cAMP) together with a number of other second messengers including phospholipase C, PI3 Kinase/Akt and ceramide synthesis [24-28].”
BackgroundPiyanova, A., Albayram, Ö., Rossi, C. A., Farwanah, H., Michel, K., Nicotera, P., Sandhoff, K., & Bilkei‐Gorzó, A. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.001 · Cited by 33
“…– CB1 (highly expressed in the central nervous system) and CB2 (preferentially expressed on immune cells), their endogenous ligands (anandamide, AEA, and 2- arachidonoylglycerol, 2-AG) and the enzymes involved in the synthesis and degradation of the endocannabinoids (Di Marzo et al., 2004).”
BackgroundThe role of central CB2 cannabinoid receptors on food intake in neonatal chicks
Emadi, L., Jonaidi, H., & Abad, E. H. A. (2011) · Journal of Comparative Physiology A · doi:10.1007/s00359-011-0676-z · Cited by 33
“Cannabinoid receptors, endocannabinoids and proteins catalyzing endocannabinoid biosynthesis and inactivation, constitute the endocannabinoid system (ECS) (Di Marzo et al. 2004).”
BackgroundCurrent pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich, E. A., Kirch, W., & Schindler, C. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708098226 · Cited by 33
“The endocannabinoid system plays an important role in the central and peripheral regulation of body weight and energy balance [Di Marzo et al. 2004].”
BackgroundRelation of Cannabis Use and Atrial Fibrillation Among Patients Hospitalized for Heart Failure
Adegbala, O. M., Adejumo, A., Olagoke, O. O., Akinjero, A., Akintoye, E. O., Alliu, S., Edo-Osagie, E., & Chatterjee, A. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.03.015 · Cited by 33
Nallapaneni, A., Liu, J., Karanth, S., & Pope, C. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.08.001 · Cited by 33
“Various forms of Cannabis have been used for both medicinal and recreational purposes for centuries (Frazzetto, 2003; Di Marzo et al., 2004; Hart, 2005).”
BackgroundThe endocannabinoid system: Body weight and metabolic regulation
Engeli, S., & Jordan, J. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80041-4 · Cited by 33
Cheer, J. F., Wassum, K. M., & Wightman, R. M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03860.x · Cited by 33
“Because WIN has higher affinity for CB2 (peripheral) receptors under certain conditions and CB2 receptors are expressed in the periphery (Di Marzo et al. 2004), the involvement of CB1 receptors in the effects of WIN needed to be established.”
Brogi, S., Corelli, F., Marzo, V. D., Ligresti, A., Mugnaini, C., Pasquini, S., & Tafi, A. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.034 · Cited by 33
Self-citationForget, B., Guranda, M., Gamaleddin, I., Goldberg, S. R., & Foll, B. L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4232-y · Cited by 33
“The endogenous cannabinoid system comprises the cannabinoid receptors (CB1R and CB2R), the genes encoding them, and the endogenous cannabinoid ligands, primarily anandamide (AEA) and 2- arachidonoylglycerol (2-AG) (Di Marzo et al. 2004; Howlett et al. 2002).”
BackgroundSimei, J. L. Q., Souza, J. D. R., Pedrazzi, J. F. C., Guimarães, F. S., Campos, A. C., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121644 · Cited by 32
Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R. J., & Torsello, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118044 · Cited by 32
Translational models of cannabinoid vapor exposure in laboratory animals
Moore, C. F., Stiltner, J. W., Davis, C. M., & Weerts, E. M. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000592 · Cited by 32
“…type 2 receptors (CB2R), their naturally occurring endogenous ligands 2-arachidonoylglycerol (2-AG) and arachindonoylethanolamide (anandamide) and enzymes fatty acid amide hydrolase and monoacylglycerol lipase (Ashton, 2001; for review, see Di Marzo et al., 2004; Bridgeman and Abazia, 2017).”
BackgroundMohammadkhani, A., & Borgland, S. L. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24770 · Cited by 32
“The endocannabinoid system consists of two well-characterized G protein-coupled receptors (GPCRs), cannabinoid receptors (CB1 and CB2), as well as their lipid-derived endocannabinoids, and enzymes for their synthesis, reuptake, and degradation (Di Marzo & Fontana, 1995; Marzo et al., 2004).”
BackgroundFAAH polymorphism (rs324420) modulates extinction recall in healthy humans: an fMRI study
Spohrs, J., Martin, U., Grön, G., Plener, P. L., & Abler, B. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01367-4 · Cited by 32
“Recently, major research advances were achieved regarding the endocannabinoid system, with its well-known pharmacological accessibility [6].”
BackgroundZareie, P., Sadegh, M., Palizvan, M. R., & Moradi‐Chameh, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0195-5 · Cited by 32
The Cannabinoid CB1 Receptor in Schizophrenia
Borgan, F., Kokkinou, M., & Howes, O. D. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.06.018 · Cited by 32
N -arachidonylethanolamide-Induced Increase in Aqueous Humor Outflow Facility
Mbye, Y. F. N., Qiao, Z., Xiao, Z., Wang, W., & Song, Z.-H. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1537 · Cited by 32
Goodfellow, C. E., Graham, S. E., Dragunow, M., & Glass, M. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22692 · Cited by 33
“…endocannabinoid synthesis and metabolism in the CNS. VC 2011 Wiley-Liss, Inc. Key words: cannabinoid receptor CB1; cannabinoid receptor CB2; endocannabinoids; central nervous system The cannabinoid system has emerged as an important therapeutic target over the past decade (Di Marzo et al., 2004).”
BackgroundGenetic Findings in Anorexia and Bulimia Nervosa
Hinney, A., Scherag, S., & Hebebrand, J. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-375003-7.00009-1 · Cited by 31
O sistema endocanabinóide: nova perspectiva no controle de fatores de risco cardiometabólico
Francischetti, E. A., & de Abreu, V. G. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006001700023 · Cited by 30
Nader, J., Rapino, C., Gennequin, B., Chavant, F., Francheteau, M., Makriyannis, A., Duranti, A., Maccarrone, M., Solinas, M., & Thiriet, N. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.014 · Cited by 31
“The discovery of the ECS has led to the development of new pharmacological tools that allow indirect stimulation of CB1/CB2 receptors by blocking metabolic degradation of AEA and 2-AG (Kathuria et al., 2003; Piomelli, 2003; Di Marzo et al., 2004; Long et al., 2009; Bisogno and Maccarrone, 2013).”
BackgroundNeuroinflammation as a possible link between cannabinoids and addiction
Rodrigues, L. C. M., Gobira, P. H., de Oliveira, A. C., Pelição, R., Teixeira, A. L., Moreira, F. A., & Campos, A. C. (2014) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.24 · Cited by 29
“The activity of these ligands is terminated by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (18).”
BackgroundCannabinoids and the Cannabinoid Receptors: An Overview
Lu, D., & Potter, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00068-5 · Cited by 31
Kind, L., & Kursula, P. (2018) · Amino Acids · doi:10.1007/s00726-018-2682-8 · Cited by 31
Auzmendi, J., Palestro, P. H., Blachman, A., Gavernet, L., Merelli, A., Talevi, A., Calabrese, G. C., Ramos, A. J., & Lazarowski, A. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00032 · Cited by 31
“Interestingly, the stimulation of the endocannabinoid system plays an important role in a variety of physiological functions and conditions such as neuronal development and plasticity, food intake, energy balance, and cell apoptosis [40-42].”
BackgroundInteractions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine
Nagy-Grócz, G., Zádor, F., Dvorácskó, S., Bohár, Z., Benyhe, S., Tömböly, C., Párdutz, Á., & Vécsei, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081617 · Cited by 31
The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives
Omura, H., Kawai, M., Shima, A., Iwata, Y., Ito, F., Masuda, T., Ohta, A., Makita, N., Omoto, K., Sugimoto, H., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.032 · Cited by 31
Mok, T. (2010) · The HKU Scholars Hub (University of Hong Kong) · Cited by 31
Herbal Marijuana Alternatives and Bath Salts—“Barely Legal” Toxic Highs
Lindsay, L., & White, M. L. (2012) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2012.09.001 · Cited by 30
Yan, W. X., Wang, X., Zhao, F. H., Zhao, P., & Kang, X. (2013) · PubMed Central · Cited by 30
Xian, X., Huang, L., Zhang, B., Wu, C., Cui, J., & Wang, Z. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447910 · Cited by 30
Amini, M., Saboory, E., Pourheydar, B., Bagheri, M., & Naderi, R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106158 · Cited by 30
Durand, E., Lecœur, C., Delplanque, J., Benzinou, M., Degraeve, F., Boutin, P., Marre, M., Balkau, B., Charpentier, G., Froguel, P., et al. (2008) · Obesity Facts · doi:10.1159/000178157 · Cited by 30
Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation
Fezza, F., Oddi, S., Tommaso, M. D., Simone, C. D., Rapino, C., Pasquariello, N., Dainese, E., Finazzi‐Agrò, A., & Maccarrone, M. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700486-jlr200 · Cited by 30
Caballero, F. J., Navarrete, C. M., Hess, S., Fiebich, B. L., Appendino, G., Macho, A., Muñóz, E., & Sancho, R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.001 · Cited by 30
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.